Genprex trades under $1 as ASCO results land
Genprex Inc. stock stayed close to Monday’s low before the next U.S. trading session, keeping the Nasdaq Capital Market gene therapy name below $1. Investors were watching new lung-cancer biomarker data, while funding remained a concern. June 2 isn’t on the Nasdaq's 2026 market holiday schedule. GNPX was last quoted at $0.7501, about 4% lower than its previous close. That puts the company’s market cap near $7.9 million. Monday’s session saw the stock drop 3.77%, opening at $0.78, hitting a high of $0.79, and bottoming at $0.72 before closing at $0.75. About 401,000 shares changed hands.